Navigation Links
BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
Date:9/24/2008

REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.

In the trial a total of 76 sputum samples were collected from four groups of patients:

1. Healthy individuals that never smoked

2. Heavy smokers with no signs of lung cancer

3. Early stage lung cancer patients (Stage 1)

4. Advanced stage lung cancer patients

The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView's automated Duet scanning station by Company personnel. The results of the test were classified as "Normal", i.e. no cancer detected and "Abnormal", i.e. Cancer detected. These results were then compared to the actual data received from the hospital of the patients' condition.

The samples included 32 cases of lung cancer patients (about half of them early stage patients) and 44 samples taken from people with no clinical evidence of lung cancer. Thirty one of the thirty two (96.9%) sick patients were correctly diagnosed as "Abnormal" and thirty six of forty four (about 82%) healthy people were correctly diagnosed as "Normal".

Project leader, Dr. Michal Daniely says:"We have gained great confidence in this test as we see a direct relationship between our results and the clinical status of the patients".

Dr. Opher Shapira, BioView's CEO commented: "We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials."

BioView lung cancer test in based on morphological and genetic analysis of sputum samples and it is running on BioView DUETTM automated scanning platform.

About BioView Ltd.

Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at http://www.bioview.co.il.

Dr. Opher Shapira

President and CEO

Tel: +972-8-936-6868

Fax: +972-8-936-6869

e-mail: opher@bioview.co.il


'/>"/>
SOURCE BioView Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
2. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
3. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
4. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
7. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , VMS ... company,s business development and sales team, exploring new opportunities for VMS to empower patients ... ... ... ...
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, ... defective respirators, according to court documents and SEC filings. A jury has ... Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
Breaking Medicine News(10 mins):